Press the gourd to rise and down: hepatitis B, hepatitis C co-infection.

NiH scientists recently published a study on hepatitis B and C co-infection in JCI.
hepatitis B, hepatitis C co-infection is not very rare, has been clinically found to use high-efficiency hepatitis C drugs to cure hepatitis C will cause the reactivation of hepatitis B, the consequences are very serious.
the authors repeated this clinical observation with a series of in vivo and in vitro animal experiments that hepatitis C virus inhibits the reproduction of hepatitis B virus, and that hepatitis B will become the new king of the mountain after the removal of hepatitis C virus with Sovaldi.
the molecular mechanism is interferon, clinically HCV cures patients with blood interferon response gene (ISG) levels can be used as a predictive biomarker of hepatitis B reactivation.
hepatitis B virus and the new crown are similar to the so-called invisible virus, that is, will not attract the attention of the infected cell immune system, will not induce the secretion of type 1 and type 3 interferon.
hepatitis C virus can induce interferon secretion, so hepatitis C this pig teammate will cause the host to secrete interferon and inhibit the proliferation of hepatitis B virus.
the source of the drug to analyze hepatitis B, hepatitis C transmission route is similar, so the incidence of co-infection is not low.
1-15% of the population is geographically infected with both viruses, significantly increasing the risk of cirrhosis and liver cancer.
although both viruses mainly infect liver cells, but the physical quality of the two, life habits are completely different.
hepatitis B is one of the smallest viruses, a little weak wind, most acute infections will be automatically eliminated.
that even if it becomes chronic hepatitis B, it will take years of persistent infection to cause host disease.
but hepatitis B as a DNA virus can be compiled into the host genome, and can form a very difficult to remove ring ccc DNA, which is its survival magic weapon.
hepatitis C is an RNA virus that reproduces only in cell fluid, and antiviral drugs are now available to completely cure hepatitis C infection within 8-12 weeks.
interferon is effective for hepatitis B and C treatment, of course, because of the emergence of Sovaldi and other god drugs hepatitis C treatment no longer need interferon, but hepatitis B treatment is also highly dependent on interferon.
Interferon can not only directly inhibit hepatitis B reproduction, tissue T, B cells siege hepatitis B infected cells, but also can induce the expression of certain DNA modification proteins such as A3A and induce cccDNA degradation, which is the only way to cure hepatitis B, so from the point of view of hepatitis B in order to maintain survival should do everything possible to avoid interferon secretion is activated.
hepatitis B virus saw hepatitis C into their boarding cell estimation and in the bank shoplifting thin thief suddenly saw a drunk man to rob the bank, the heart secretly thought I was dead.
because yelling about the hepatitis C virus will attract police interferon, although not necessarily will be caught but the living environment deteriorated a lot.
treatment of hepatitis C is one of the most successful cases in the history of drug research, with very few drugs yielding more than 95% of the response rates, but current hepatitis C therapy can reach this level in all genotypes.
these treatments are not just to keep the virus below the detection line, like AIDS drugs, but to cure it completely.
but hepatitis C-B co-infection limits this strategy, as the reactivation of hepatitis B may be more severe than hepatitis C infection.
to a certain extent hepatitis C hepatitis B of course human flesh bomb, killing hepatitis C will detonate hepatitis B.
these viruses are only tens of thousands of base pairs, but their design is amazingly sophisticated and the complexity of their survival strategies is breathtaking.
hepatitis B has become one of the world's largest liver diseases after the cure of hepatitis C, but hepatitis B is mainly distributed in developing countries and is not as important as NASH.
the current hepatitis B treatment only about 10% of the clinical cure rate (i.e., anti-transocerosis), but there is no complete elimination of cccDNA therapy.
RNAi technology shows better prospects, but from the results of several smaller clinical trials so far, australia's anti-transocean rate is no more than 20%.
the study showed that hepatitis C virus could theoretically be used as a treatment for hepatitis B, but the strategy of jumping from a fire pit to a puddle was not worth it, and there was no treatment window for the virus as a drug.
hepatitis C is not the only "drug" that induces interferon, the targeted delivery of HBD is not available in other therapies, " he said.
the development of liver-targeted delivery interferons may be a strategy, and small molecule drugs that activate TLR, STING, and RIG-1, natural immune system alarms, are also in clinical trials, although these drugs also have systemic toxicity problems.
small molecule drugs that only induce interferon secretion in infected liver cells are a deducing direction.
.